Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients

AIDS Research and Human Retroviruses

Volumn 21, Issue 5, 2005, Pages 407-409

  Ranieri, Roberto ^a,b   Veronelli, A ^a   Santambrogio, C ^a   Pontiroli, A E ^a  

^a Azienda Ospedaliera San Paolo   (Italy)

^b Ospedale San Paolo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INCIDENCE; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ADULT; AGED; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; ORTHOMYXOVIRIDAE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

EID: 20444368775     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.407     Document Type: Article

References (16)

1. Simberkoff ME, El Sadr W, Schiffman G, and Rahal JJ Jr: Streptococcus pneumoniae infections and bacteremia in patients with acquired immunodeficiency syndrome with report of a pneumococcal vaccine failure. Am Rev Respir Dis 1984;130:1174-1176.
2. Redd SC, Rutherford GW III, Sande MA, et al.: The role of immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990;162:1012-1017.
3. Kaplan JE, Hanson D, Dworkin MS, et al: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl.):S5-14.
4. Paul S, Gilbert HM, Ziecheck W, et al: The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1998;12:F217-223.
5. Taconelli E, Tumbarello M, de Gaetan K, et al: Highly active antiretroviral therapy decreases the incidence of bacteremia in human immunodeficiency virus-infected individuals. Clin Infect Dis 1998;27:901-902.
6. Abadi J, Friedman J, Mageed RA, Jefferis R, Rodriguez-Barradas MC, and Pirofski L: Human antibodies elicited by a pneumococcal vaccine express idiotypic determinants indicative of Vh3 gene segment usage. J Infect Dis 1999;178:707-716.
7. Dworkin MS, Ward JW, Hanson DL, Jones DL, and Kaplan JE: Pneumococcal disease among human immunodeficiency virus-infected persons: Incidence, risk factors and impact of vaccination: Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis 2001;32:794-800.
8. Gardner P, Pickering LK, Orenstein WA, Gershon AA, and Nichol KL: Guidelines for quality standard immunization. Clin Infect Dis 2002;35:503-511.
9. Masur H, Kaplan JE, and Holmes KK: Guidelines for preventing opportunistic infections among HIV-infected persons-2002; recommendations of the US Public Health Service and the Infectious Diseases Society of America. US Public Health Service/Infectious Diseases Society of America. Ann Intern Med 2002;137:435-478.
10. Rodriguez-Barradas MC, Alexandraki I, Nazir T, et al.: Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003;37:438-447.
11. Feikin DR, Elie CM, Goetz MB, et al.: Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide-vaccine among HIV-infected adults. Vaccine 2001;20:545-553.
12. Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, and Janoff EN: Reimmunization with 23-valent pneumococcal vaccine for patients infected with immunodeficiency virus type 1: Clinical, immunological, and virological responses. Clin Infect Dis 2002;34:813-821.
13. Amendola A, Tanzi E, Zappa A, et al: Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected former drug users. Vaccine 2002;20:3720-3724.
14. French N, Gilks CF, Mujugira A, Fasching C, O'Brien J, and Janoff EN: Pneumococcal vaccination in HIV-1-infected adults in Uganda: Humoral response and two vaccine failures. AIDS 1998;12:1683-1689.
15. Gordon BS, Miller DE, Day RB, et al.: Pulmonary immunoglobulin responses to Streptococcus pneumoniae are altered but not reduced in human immunodeficiency virus-infected Malawian adults. J Infect Dis 2003;188:666-670.
16. Katzenstein TL, Pedersen C, Nielsen C, Lundgren J, Jakobsen PH, and Gerstoft J: Longitudinal serum HIV-RNA quantification correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996;10:167-173.